WO2006021443A3 - Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator - Google Patents

Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator Download PDF

Info

Publication number
WO2006021443A3
WO2006021443A3 PCT/EP2005/009197 EP2005009197W WO2006021443A3 WO 2006021443 A3 WO2006021443 A3 WO 2006021443A3 EP 2005009197 W EP2005009197 W EP 2005009197W WO 2006021443 A3 WO2006021443 A3 WO 2006021443A3
Authority
WO
WIPO (PCT)
Prior art keywords
macrolide
receptor blocker
composition
cell immunomodulator
pharmaceutically acceptable
Prior art date
Application number
PCT/EP2005/009197
Other languages
French (fr)
Other versions
WO2006021443A2 (en
Inventor
Margaret Forney Prescott
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Margaret Forney Prescott
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh, Margaret Forney Prescott filed Critical Novartis Ag
Publication of WO2006021443A2 publication Critical patent/WO2006021443A2/en
Publication of WO2006021443A3 publication Critical patent/WO2006021443A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a pharmaceutical compositions comprising an AT1 receptor blocker or pharmaceutically acceptable salts thereof and macrolide T-cell immunomodulator or immunosuppressant agent, e.g. pimecrolimus optionally in the presence of a pharmaceutically acceptable carrier.
PCT/EP2005/009197 2004-08-26 2005-08-25 Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator WO2006021443A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60454504P 2004-08-26 2004-08-26
US60/604,545 2004-08-26

Publications (2)

Publication Number Publication Date
WO2006021443A2 WO2006021443A2 (en) 2006-03-02
WO2006021443A3 true WO2006021443A3 (en) 2006-12-21

Family

ID=35645627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/009197 WO2006021443A2 (en) 2004-08-26 2005-08-25 Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator

Country Status (1)

Country Link
WO (1) WO2006021443A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064942A1 (en) * 1998-03-26 2001-01-03 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparations
WO2001097805A2 (en) * 2000-06-22 2001-12-27 Novartis Ag Solid valsartan pharmaceutical compositions
WO2003066606A1 (en) * 2002-02-04 2003-08-14 Novartis Ag Salts of valsartan
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1064942A1 (en) * 1998-03-26 2001-01-03 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparations
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
WO2001097805A2 (en) * 2000-06-22 2001-12-27 Novartis Ag Solid valsartan pharmaceutical compositions
WO2003066606A1 (en) * 2002-02-04 2003-08-14 Novartis Ag Salts of valsartan

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAMAR P ET AL: "COINHIBITION OF IMMUNE AND RENIN-ANGIOTENSIN SYSTEMS REDUCES THE PACE OF GLOMERULOSCLEROSIS IN THE RAT REMNANT KIDNEY", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, WILLIAMS AND WILKINS, BALTIMORE, MD, US, vol. 10, no. 11, January 1999 (1999-01-01), pages S234 - S238, XP000874983, ISSN: 1046-6673 *

Also Published As

Publication number Publication date
WO2006021443A2 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
IL181301A0 (en) Cyclopamine analogues, pharmaceutical compositions comprising them and uses thereof
WO2006084164A3 (en) Gastric retention and controlled release delivery system
WO2006023627A8 (en) Rapamycin polymorph ii and uses thereof
WO2008057579A3 (en) Dosage forms and co-administration of an opioid agonist and an opioid antagonist
WO2007086001A3 (en) Novel pyridine derivatives
PL1792927T3 (en) Novel block copolymer, micelle preparation, and anticancer agent containing the same as active ingredient
WO2007146248A3 (en) Stable laquinimod preparations
EP1783137A4 (en) Galactose derivative, drug carrier and medicinal composition
EP1891141A4 (en) Triblock copolymers for cytoplasmic delivery of gene-based drugs
IL177533A (en) Benzimidazole derivatives, their preparation and pharmaceutical compositions comprising them
EP1922019A4 (en) Tri-block copolymers for nanosphere-based drug delivery
HK1118016A1 (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
WO2006039163A3 (en) Cyclosporin alkyne analogues and their pharmaceutical uses
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
IL177120A0 (en) Formulations for poorly soluble drugs
HK1123789A1 (en) Azabicyclic derivatives, preparation method thereof and pharmaceutical compositions containing same
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2007050802A3 (en) Novel opioid antagonists
IL210756A0 (en) Carbostyril compound, process for their preparation and pharmaceutical compositions containing them
WO2008084698A1 (en) Tacrolimus sustained release pharmaceutical composition
EP2332526A3 (en) Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
EP1809291A4 (en) Pharmaceutical compositions for transdermal delivery
WO2008051564A3 (en) Crystalline forms of palonosetron hydrochloride
IL181683A0 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2008003050A3 (en) Gallium nitrate formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase